本帖最后由 老马 于 2013-3-13 13:43 编辑 / z* N1 l, H1 m9 X" X* G% G
t- i7 E: B- e& s, l9 O8 Z0 k
健择（吉西他滨）+顺铂+阿瓦斯汀
$ R- U! Y/ U1 y: z F Gemzar +Cisplatin + Avastin. a. A$ K& i' H* h& A3 _( h
http://annonc.oxfordjournals.org/content/21/9/1804.full% q# u! n6 {8 g# v. N& f# C9 [
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) + F1 p3 n1 s n/ r, {; F* m
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ u4 k( a+ G( k9 i: yResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
4 k, S! d. o- I0 h {
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1141)
+ Z: o; I$ {0 A L
华为网盘附件：
8 K& U) Q& Q' {【华为网盘】ava.JPG% b7 C3 e) B" Z1 c' d% L2 N! ]: w
|
11011102001537 )
显身卡
